To date, AT has primarily responded to surrogate measures of total tumour burden, for example changes in the serum tumour marker PSA to direct abiraterone therapy in prostate cancer, and AT in ACTOv will be based on changes in CA125. This evidence concerns the gene KLK3 and prostate cancer.